TW200640901A - Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity - Google Patents

Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity

Info

Publication number
TW200640901A
TW200640901A TW095105088A TW95105088A TW200640901A TW 200640901 A TW200640901 A TW 200640901A TW 095105088 A TW095105088 A TW 095105088A TW 95105088 A TW95105088 A TW 95105088A TW 200640901 A TW200640901 A TW 200640901A
Authority
TW
Taiwan
Prior art keywords
compound
diseases
limiting example
therapy
solvates
Prior art date
Application number
TW095105088A
Other languages
English (en)
Inventor
Brian F Mcguinness
Stuart B Rosenblum
Joseph A Kozlowski
Gopinadhan N Anilkumar
Seong-Heon Kim
Neng-Yang Shih
Chung-Her Jenh
Paul J Zavodny
Douglas W Hobbs
Guizhen Dong
Yuefei Shao
Lisa Guise Zawacki
Cangming Yang
Carolyn Dilanni Carroll
Original Assignee
Schering Corp
Pharmacopeia Drug Discovery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Pharmacopeia Drug Discovery filed Critical Schering Corp
Publication of TW200640901A publication Critical patent/TW200640901A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW095105088A 2005-02-16 2006-02-15 Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity TW200640901A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65333705P 2005-02-16 2005-02-16

Publications (1)

Publication Number Publication Date
TW200640901A true TW200640901A (en) 2006-12-01

Family

ID=36593711

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095105088A TW200640901A (en) 2005-02-16 2006-02-15 Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity

Country Status (13)

Country Link
US (1) US7776862B2 (zh)
EP (1) EP1856097B1 (zh)
JP (1) JP2008530218A (zh)
KR (1) KR20070107056A (zh)
CN (1) CN101213185A (zh)
AR (1) AR055195A1 (zh)
AU (1) AU2006214378A1 (zh)
CA (1) CA2598457A1 (zh)
IL (1) IL185074A0 (zh)
MX (1) MX2007009946A (zh)
TW (1) TW200640901A (zh)
WO (1) WO2006088919A2 (zh)
ZA (1) ZA200706793B (zh)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1663197T3 (pl) 2003-09-09 2008-09-30 Biogen Idec Int Gmbh Zastosowanie pochodnych kwasu fumarowego do leczenia niewydolności serca oraz astmy
MXPA06011722A (es) 2004-04-13 2007-01-25 Incyte Corp Derivados de piperazinilpiperidina como antagonistas del receptor de quimiocina.
US7635698B2 (en) * 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US7880002B2 (en) 2004-12-29 2011-02-01 Millennium Pharmaceuticals, Inc. Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
WO2006088840A1 (en) * 2005-02-16 2006-08-24 Schering Corporation Novel heterocyclic substituted pyridine or phenyl compounds with cxcr3 antagonist activity
CN101189238A (zh) * 2005-02-16 2008-05-28 先灵公司 具有cxcr3拮抗剂活性的哌嗪-哌啶
TW200714610A (en) 2005-02-16 2007-04-16 Univ Maryland CXCR3 is a gliadin receptor
CN101189225A (zh) * 2005-02-16 2008-05-28 先灵公司 具有cxcr3拮抗剂活性的杂芳基取代的吡嗪基-哌嗪-哌啶
CN101163692B (zh) * 2005-02-16 2012-01-18 先灵公司 具有cxcr3拮抗活性的杂环取代的哌嗪
WO2006088921A2 (en) * 2005-02-16 2006-08-24 Schering Corporation Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity
ATE546445T1 (de) * 2005-10-11 2012-03-15 Schering Corp Substituierte heterocyclische verbindungen mit cxcr3-antagonistischer wirkung
CN101460482B (zh) * 2006-03-21 2013-03-27 默沙东公司 具有cxcr3拮抗剂活性的杂环取代的吡啶化合物
AR061975A1 (es) * 2006-07-14 2008-08-10 Schering Corp Compuestos de piperazina 1,4-sustituida con actividad antagonista de cxcr3, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor de quimioquina cxcr3
US20120157466A1 (en) * 2006-12-22 2012-06-21 Qingbei Zeng Heterocyclic compounds with cxcr3 antagonist activity
US8138191B2 (en) 2007-01-11 2012-03-20 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
LT2653873T (lt) 2007-02-08 2022-10-10 Biogen Ma Inc. Kompozicijos ir naudojimas, skirti išsėtinei sklerozei gydyti
EP2125750B1 (en) * 2007-02-26 2014-05-21 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2136832B1 (en) 2007-03-26 2015-09-02 General Regeneratives Limited Methods for promoting protection and regeneration of bone marrow using cxcl9 and anti-cxcl9 antibodies
ES2395081T3 (es) * 2007-07-26 2013-02-08 Vitae Pharmaceuticals, Inc. Síntesis de inhibidores de la 11beta-hidroxiesteroide deshidrogenasa de tipo 1
AR069207A1 (es) * 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
US8440658B2 (en) 2007-12-11 2013-05-14 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1
CN101896461A (zh) * 2007-12-13 2010-11-24 安姆根有限公司 γ分泌酶调节剂
WO2009079797A1 (en) 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
TW200934490A (en) * 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
EP2252601B1 (en) * 2008-01-24 2012-12-19 Vitae Pharmaceuticals, Inc. Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CA2714532A1 (en) * 2008-02-11 2009-08-20 Vitae Pharmaceuticals, Inc. 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
WO2009102460A2 (en) * 2008-02-15 2009-08-20 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
PE20091576A1 (es) * 2008-02-19 2009-11-05 Sanofi Aventis DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3
CA2718264A1 (en) * 2008-03-18 2009-09-24 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
US8569292B2 (en) 2008-05-01 2013-10-29 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
ES2421537T3 (es) 2008-05-01 2013-09-03 Vitae Pharmaceuticals Inc Inhibidores cíclicos de la 11beta-hidroxiesteroide deshidrogenasa 1
US8242111B2 (en) * 2008-05-01 2012-08-14 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
JP5538365B2 (ja) 2008-05-01 2014-07-02 ヴァイティー ファーマシューティカルズ,インコーポレイテッド 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状阻害剤
DE102008022221A1 (de) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
WO2010005783A1 (en) * 2008-07-08 2010-01-14 Boehringer Ingelheim International Gmbh Pyrrolidinyl and piperidinyl compounds useful as nhe-1 inhibitors
JP5777030B2 (ja) 2008-07-25 2015-09-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 11β−ヒドロキシステロイドデヒドロゲナーゼ1の阻害剤
PL2324018T3 (pl) 2008-07-25 2014-02-28 Boehringer Ingelheim Int Cykliczne inhibitory dehydrogenazy 11 beta-hydroksysteroidowej typu 1
JP5478499B2 (ja) * 2008-10-27 2014-04-23 田辺三菱製薬株式会社 新規アミド誘導体およびその医薬としての用途
WO2010081851A1 (en) 2009-01-14 2010-07-22 Genoscience Pharma Piperidin-4-ylpiperazine compounds for the treatment of hcv infection
EP2393807B1 (en) 2009-02-04 2013-08-14 Boehringer Ingelheim International GmbH Cyclic inhibitors of 11 -hydroxysteroid dehydrogenase 1
TW201039034A (en) * 2009-04-27 2010-11-01 Chunghwa Picture Tubes Ltd Pixel structure and the method of forming the same
GEP20156309B (en) * 2009-04-30 2015-07-10 Vitae Pharmaceuticals Inc Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
UA109255C2 (ru) 2009-04-30 2015-08-10 Берінгер Інгельхайм Інтернешнл Гмбх Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1
JP5656986B2 (ja) 2009-06-11 2015-01-21 ヴァイティー ファーマシューティカルズ,インコーポレイテッド 1,3−オキサジナン−2−オン構造に基づく11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状阻害剤
CN102458402B (zh) 2009-06-12 2013-10-02 百时美施贵宝公司 用作激酶调节剂的烟酰胺化合物
EP2448928B1 (en) 2009-07-01 2014-08-13 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
WO2011068171A1 (ja) * 2009-12-03 2011-06-09 第一三共株式会社 二環性含窒素飽和へテロ環誘導体
CA2999435A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
EP2582698B1 (en) 2010-06-16 2016-09-14 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
JP5813106B2 (ja) 2010-06-25 2015-11-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 代謝障害の処置のための11−β−HSD1のインヒビターとしてのアザスピロヘキサノン
JP5874124B2 (ja) 2010-06-28 2016-03-02 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 緑内障の処置に使用するための薬学的組成物
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
CA2813671A1 (en) 2010-11-02 2012-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
CA2852160A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
CA2861020C (en) 2012-02-02 2018-07-17 Actelion Pharmaceuticals Ltd 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives and their use as cxcr3 receptor modulators
EP2948134B1 (en) 2013-01-24 2020-03-04 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mtor inhibitors
ES2671323T3 (es) 2013-07-22 2018-06-06 Idorsia Pharmaceuticals Ltd Derivados 1¿(piperazin¿1¿il)¿2¿([1,2,4]triazol¿1¿il)¿etanona
PT3087051T (pt) * 2013-12-24 2020-10-21 Oncotartis Inc Compostos de nicotinamida e benzamida e métodos para utilizar os mesmos
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
AR099789A1 (es) 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
KR20170009992A (ko) * 2014-06-30 2017-01-25 도요 고무 고교 가부시키가이샤 밀폐형 2차 전지의 변형 검출 센서, 밀폐형 2차 전지, 및, 밀폐형 2차 전지의 변형 검출 방법
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
ES2709985T3 (es) 2015-01-15 2019-04-22 Idorsia Pharmaceuticals Ltd Derivados de hidroxialquil-piperazina como moduladores del receptor CXCR3
CN112569242A (zh) 2015-04-02 2021-03-30 普罗克斯马根有限责任公司 用于癌症的新治疗
TW202246215A (zh) 2015-12-18 2022-12-01 美商亞德利克斯公司 作為非全身tgr5促效劑之經取代之4-苯基吡啶化合物
EP3565520A4 (en) 2017-01-06 2020-08-19 Palvella Therapeutics, Inc. Anhydrous compositions of MTOR inhibitors and method of use
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク. mTOR阻害剤の無水組成物および使用方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010091A2 (en) 1991-11-14 1993-05-27 Glaxo Group Limited Piperidine acetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
AU3351293A (en) * 1992-01-21 1993-08-03 Glaxo Group Limited Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
US6124319A (en) 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
AR013693A1 (es) 1997-10-23 2001-01-10 Uriach & Cia Sa J Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria
BR0010304A (pt) * 1999-05-04 2002-02-13 Schering Corp Derivados de piperazina úteis como antagonistas do ccr5
US20020018776A1 (en) 2000-04-14 2002-02-14 Millennium Pharmaceuticals, Inc. Method of treating graft rejection using inhibitors of CXCR3 function
EA007538B1 (ru) 2000-12-11 2006-10-27 Туларик Инк. Антагонисты cxcr3
US6469002B1 (en) 2001-04-19 2002-10-22 Millennium Pharmaceuticals, Inc. Imidazolidine compounds
GB0203994D0 (en) 2002-02-20 2002-04-03 Celltech R&D Ltd Chemical compounds
AU2003236354A1 (en) 2002-04-03 2003-10-13 Sumitomo Pharmaceuticals Co., Ltd. Novel blood sugar controller and method of screening the same
US7244555B2 (en) 2002-05-14 2007-07-17 Renovak Inc Systems and methods for identifying organ transplant risk
JP2005530813A (ja) 2002-06-03 2005-10-13 スミスクライン・ビーチャム・コーポレイション イミダゾリウムcxcr3阻害剤
KR20060009390A (ko) 2003-06-13 2006-01-31 쉐링 악티엔게젤샤프트 Ccr-5 길항제로서의 퀴놀릴 아미드 유도체
CN101189238A (zh) 2005-02-16 2008-05-28 先灵公司 具有cxcr3拮抗剂活性的哌嗪-哌啶
CN101189225A (zh) 2005-02-16 2008-05-28 先灵公司 具有cxcr3拮抗剂活性的杂芳基取代的吡嗪基-哌嗪-哌啶
CN101163692B (zh) 2005-02-16 2012-01-18 先灵公司 具有cxcr3拮抗活性的杂环取代的哌嗪
WO2006088921A2 (en) 2005-02-16 2006-08-24 Schering Corporation Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity
WO2006088840A1 (en) 2005-02-16 2006-08-24 Schering Corporation Novel heterocyclic substituted pyridine or phenyl compounds with cxcr3 antagonist activity
WO2006088920A1 (en) 2005-02-16 2006-08-24 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
ATE546445T1 (de) 2005-10-11 2012-03-15 Schering Corp Substituierte heterocyclische verbindungen mit cxcr3-antagonistischer wirkung
CN101460482B (zh) 2006-03-21 2013-03-27 默沙东公司 具有cxcr3拮抗剂活性的杂环取代的吡啶化合物
AR061975A1 (es) 2006-07-14 2008-08-10 Schering Corp Compuestos de piperazina 1,4-sustituida con actividad antagonista de cxcr3, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor de quimioquina cxcr3
US20120157466A1 (en) 2006-12-22 2012-06-21 Qingbei Zeng Heterocyclic compounds with cxcr3 antagonist activity

Also Published As

Publication number Publication date
IL185074A0 (en) 2007-12-03
WO2006088919A3 (en) 2006-11-02
AR055195A1 (es) 2007-08-08
MX2007009946A (es) 2007-09-26
ZA200706793B (en) 2008-11-26
AU2006214378A1 (en) 2006-08-24
CN101213185A (zh) 2008-07-02
EP1856097B1 (en) 2012-07-11
JP2008530218A (ja) 2008-08-07
EP1856097A2 (en) 2007-11-21
CA2598457A1 (en) 2006-08-24
US7776862B2 (en) 2010-08-17
KR20070107056A (ko) 2007-11-06
WO2006088919A2 (en) 2006-08-24
US20070021611A1 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
TW200640901A (en) Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
TW200640902A (en) Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
TW200640903A (en) Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity
TW200640906A (en) Heteroaryl substituted pyrazinyl-piperazine-piperidines with CXCR3 antagonist activity
ZA200706796B (en) Novel heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity
TW200640907A (en) Heterocyclic substituted piperazines with CXCR3 antagonist activity
MX2008012161A (es) Compuestos heterociclicos de piridina sustituida con actividad antagonista de cxcr3.
WO2006088836A3 (en) Piperazine-piperidines with cxcr3 antagonist activity
ATE546445T1 (de) Substituierte heterocyclische verbindungen mit cxcr3-antagonistischer wirkung
MX2009006871A (es) Compuestos heterociclicos con actividad antagonista de cxcr3.
DE602006005136D1 (de) Als medikamente für die behandlung von autoimmunerkrankungen geeignete substituierte pyridoä2,3-düpyrimidinderivate
TNSN05252A1 (en) Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders : process for their preparation and pharmaceutical compositions containing them
ATE388952T1 (de) Imidazopyridazinon- und imidazopyridonderivate, deren herstellung und deren verwendung als arzneimittel
MX9306271A (es) Carbamatos de rapamicina y composicion farmaceutica que los incluye.
MY142804A (en) Nk1 antagonists
AR039823A1 (es) Moduladores ureicos derivados de la amino-tetralina del receptor vr1 de vanilloides
NO331174B1 (no) Substituerte 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazinderivater og deres anvendelse som neurokininantagonister
WO2006069805A3 (en) Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment
BRPI0411825B8 (pt) inibidores de p38 quinase a base de heterociclo de 5 elementos, seus processos de preparação e seus usos, bem como composição farmacêutica
PL1699800T3 (pl) Bicykliczne heterocykliczne inhibitory kinazy p-38
ATE439837T1 (de) 5-gliedrige heterocyclische p-38 inhibitoren
TW200602339A (en) Substituted diaza-spiro-[5.5]-undecane derivatives and their use as neurokinin antagonists
ES2087038B1 (es) Nuevas piperidinas con actividad antagonista del paf.
UA42731C2 (uk) Арилалкілтіадіазинони, спосіб їх отримання, фармацевтична композиція, спосіб її отримання, спосіб лікування
MX2023002907A (es) Compuestos heterociclicos como inhibidores del bromodominio cbp/ep300.